Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $1.0 million.

  • Insight Molecular Diagnostics' Capital Expenditures rose 110689.66% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 23922.26%. This contributed to the annual value of $516000.0 for FY2024, which is 8362.99% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Capital Expenditures is $1.0 million, which was up 110689.66% from $349000.0 recorded in Q2 2025.
  • Insight Molecular Diagnostics' Capital Expenditures' 5-year high stood at $1.6 million during Q1 2022, with a 5-year trough of -$564000.0 in Q3 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' median Capital Expenditures value was $394000.0 (recorded in 2021), while the average stood at $500529.4.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Capital Expenditures soared by 181363.64% in 2021 and then tumbled by 16565.77% in 2023.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Capital Expenditures stood at $401000.0 in 2021, then surged by 100.0% to $802000.0 in 2022, then crashed by 67.08% to $264000.0 in 2023, then decreased by 18.94% to $214000.0 in 2024, then soared by 390.65% to $1.0 million in 2025.
  • Its Capital Expenditures stands at $1.0 million for Q3 2025, versus $349000.0 for Q2 2025 and $307000.0 for Q1 2025.